|
Title
|
Publication Date
|
Price
|
Relevance
|
|
CNS Drug Discoveries: Neurodegenerative Disorders
|
Nov 2006 |
£795 |
100% |
|
CNS Drug Discoveries: Alzheimer's Disease Chapter
|
Aug 2008 |
£595 |
99% |
|
CNS Drug Discoveries: Schizophrenia Chapter
|
Aug 2008 |
£595 |
99% |
|
CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder (ADHD)
|
Nov 2006 |
£795 |
99% |
|
CNS Drug Discoveries: Depression Chapter
|
Aug 2008 |
£595 |
99% |
|
CNS Drug Discoveries: Parkinson's Disease Chapter
|
Aug 2008 |
£595 |
99% |
Blood-Brain Barrier
Bridging Options for Drug Discovery and Development
|
May 2008 |
£710 |
98% |
|
CNS Drug Discoveries: what the future holds
|
Aug 2008 |
£1,795 |
95% |
|
Biomarkers: Applications and trends that are revolutionising drug discovery and development
|
Aug 2010 |
£695 |
87% |
Drug Discovery and Preclinical Molecules by Therapy Area
Innovation Focuses on Stem Cell Therapies and Gene Therapies
|
Feb 2011 |
£2,215 |
86% |
Nanobiotechnology (2 parts)
Applications, Markets and Companies
|
Jan 2012 |
£3,240 |
86% |
Proteomics (2 parts)
Technologies, Markets and Companies
|
Jan 2012 |
£3,240 |
86% |
CNS Lymphoma - Pipeline Review
H1 2012
|
Jan 2012 |
£325 |
86% |
Alzheimer's Disease
Pipeline Assessment and Market Forecasts to 2017
|
Nov 2010 |
£1,265 |
86% |
Stem Cells Market Trends 2010
Drug Discovery/Toxicity Screening and Regenerative Medicine
|
Apr 2010 |
£1,015 |
85% |
|
Drug Delivery Technology: Revolutionizing CNS Therapies
|
Dec 2007 |
£945 |
85% |
Ion Channel Drug Discovery
Therapeutic Opportunities & Technology Progress
|
May 2004 |
£830 |
85% |
|
CNS Biomarkers: Players, products and prospects (Volume II)
|
Aug 2008 |
£0 |
85% |
Migraine Therapeutics
Pipeline Assessment and Market Forecasts to 2016
|
Jul 2010 |
£1,265 |
85% |
|
Parkinson's Disease – Pipeline Assessment and Market Forecasts to 2016
|
Jun 2010 |
£1,265 |
83% |
|
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects
|
Aug 2008 |
£1,495 |
83% |
Cell therapy (2 parts)
Technologies, Markets and Companies
|
Jan 2012 |
£3,560 |
82% |
Epilepsy Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Dec 2011 |
£2,215 |
82% |
|
Biomarkers
|
Aug 2011 |
£3,035 |
81% |
|
Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
|
Aug 2004 |
£1,420 |
80% |
Drug Delivery to CNS
Technologies, Markets and Companies
|
Jan 2012 |
£1,945 |
80% |
Neuroprotection (2 parts)
Technologies, Markets and Companies
|
Jan 2012 |
£3,240 |
79% |
Convergence of Biomarkers and Diagnostics, The
Therapy Area Analyses, Key Products and Future Trends
|
Apr 2008 |
£2,425 |
79% |
|
Approaches to Reducing Phase II Attrition
|
May 2009 |
£2,370 |
79% |
Dementia Therapeutics
Pipeline Assessment and Market Forecasts to 2017
|
Mar 2011 |
£1,265 |
79% |
